- Home
- AIFF vs ICCC Comparison
AIFF vs ICCC Comparison
Compare AIFF & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFF
- ICCC
- Stock Information
- Founded
- AIFF 2006
- ICCC 1982
- Country
- AIFF Canada
- ICCC United States
- Employees
- AIFF N/A
- ICCC N/A
- Industry
- AIFF
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- AIFF
- ICCC Health Care
- Exchange
- AIFF NYSE
- ICCC Nasdaq
- Market Cap
- AIFF 24.9M
- ICCC 28.0M
- IPO Year
- AIFF N/A
- ICCC 1987
- Fundamental
- Price
- AIFF $2.93
- ICCC $3.66
- Analyst Decision
- AIFF
- ICCC
- Analyst Count
- AIFF 0
- ICCC 0
- Target Price
- AIFF N/A
- ICCC N/A
- AVG Volume (30 Days)
- AIFF 65.7K
- ICCC 14.5K
- Earning Date
- AIFF 11-14-2024
- ICCC 11-13-2024
- Dividend Yield
- AIFF N/A
- ICCC N/A
- EPS Growth
- AIFF N/A
- ICCC N/A
- EPS
- AIFF N/A
- ICCC N/A
- Revenue
- AIFF $74,000.00
- ICCC $23,838,002.00
- Revenue This Year
- AIFF N/A
- ICCC N/A
- Revenue Next Year
- AIFF N/A
- ICCC N/A
- P/E Ratio
- AIFF N/A
- ICCC N/A
- Revenue Growth
- AIFF N/A
- ICCC 46.37
- 52 Week Low
- AIFF $2.74
- ICCC $3.34
- 52 Week High
- AIFF $15.90
- ICCC $5.59
- Technical
- Relative Strength Index (RSI)
- AIFF 42.66
- ICCC 54.28
- Support Level
- AIFF $2.92
- ICCC $3.40
- Resistance Level
- AIFF $3.36
- ICCC $3.69
- Average True Range (ATR)
- AIFF 0.34
- ICCC 0.15
- MACD
- AIFF -0.02
- ICCC 0.01
- Stochastic Oscillator
- AIFF 9.52
- ICCC 65.12
About AIFF FIREFLY NEUROSCIENCE INC
Firefly Neuroscience Inc is an AI company developing innovative neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support better outcomes for people suffering from mental illnesses and cognitive disorders.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.